As cisplatin is a major component of chemotherapy regimens in NPC, and protocols using IFNβ as maintenance therapy have an inferior rate of systemic relapses [7], further studies analyzing the effect of IFNβ on the activity of chemotherapeutics in NPC should be of major interest. This evidence concerns the gene IFNB1 and nasopharyngeal carcinoma.